Skip to main content
Midas Edge

IONIS PHARMACEUTICALS INC

For the period ended Mar 31, 2026. Filed Apr 29, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed Apr 29, 2026

IONS$28.19-9.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

Common Stock · Additional · Accumulated Other · Total
DescriptionSharesAmountPaid in CapitalComprehensive LossAccumulated DeficitStockholders' Equity
Balance at December 31, 2024157,909$158$2,868,812$(30,811)$(2,249,808)$588,351
Net loss----(146,938)(146,938)
Change in unrealized gains, net of tax---1,630-1,630
Foreign currency translation---232-232
Issuance of common stock in connection with employee stock plans, net1,13212,241--2,242
Stock-based compensation expense--30,209--30,209
Balance at March 31, 2025159,041$159$2,901,262$(28,949)$(2,396,746)$475,726
Balance at December 31, 2025163,305$163$3,145,402$(25,281)$(2,631,195)$489,089
Net loss----(92,528)(92,528)
Change in unrealized losses, net of tax---(5,604)-(5,604)
Foreign currency translation---(138)-(138)
Issuance of common stock in connection with employee stock plans, net2,597357,299--57,302
Stock-based compensation expense--43,293--43,293
Balance at March 31, 2026165,902$166$3,245,994$(31,023)$(2,723,723)$491,414
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.